CLYM

Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutic antibodies for immune-mediated diseases. Based in King of Prussia, Pennsylvania, the company's lead program, budoprutug, is a monoclonal antibody targeting IL-17A/F designed to treat moderate to severe plaque psoriasis and potentially other inflammatory conditions. Climb Bio leverages its expertise in immunology to advance candidates addressing unmet needs in dermatology and other therapeutic areas. The company focuses on precision medicine approaches using biomarkers to identify patients most likely to benefit from its therapies.